CG Oncology (CGON) Projected to Post Quarterly Earnings on Tuesday

CG Oncology (NASDAQ:CGON) is projected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect CG Oncology to post earnings of ($0.37) per share and revenue of $0.11 million for the quarter.

CG Oncology Stock Down 2.5 %

Shares of NASDAQ CGON opened at $27.05 on Monday. CG Oncology has a 12 month low of $23.91 and a 12 month high of $46.99. The business’s 50 day moving average is $28.08 and its two-hundred day moving average is $32.15.

Insider Buying and Selling

In other news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CGON shares. TD Cowen initiated coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $66.00 target price on shares of CG Oncology in a research note on Friday, December 6th. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of CG Oncology in a research note on Friday, January 10th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, CG Oncology currently has a consensus rating of “Buy” and a consensus price target of $63.88.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.